Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections
A Phase 2, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety, and PK of 2 Dose Regimens of TP-434 Compared With Ertapenem in Adult Community-Acquired Complicated Intra-abdominal Infections
Sponsor: Tetraphase Pharmaceuticals, Inc
This PHASE2 trial investigates Complicated Intra-abdominal Infection and is currently completed. Tetraphase Pharmaceuticals, Inc leads this study, which shows 8 recorded versions since 2011 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Feb 2022 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jan 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tetraphase Pharmaceuticals, Inc
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ahmedabad, India , Bangalore, India , Bucharest, Romania , Butte, United States , Byala, Bulgaria , Daugavpils, Latvia , Denver, United States , Detroit, United States , Fort Mumbai, India , Hyderabad, India and 16 more locations